A Phase 1/2, open label trial to investigate the safety, tolerability, and preliminary efficacy of EIS-12656 as single agent and in combination with a poly-ADP ribose polymerase (PARP) inhibitor or trastuzumab deruxtecan (T-DXd), an antibody drug